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Abstract 
 
Background: The molecular mechanisms underpinning the 
progesterone-triggering mood symptoms in women with 
premenstrual dysphoric disorder (PMDD) are unknown. Cell 
metabolism is a potential source of variability. Very little is known 
about the effect of progesterone sensitivity on the metabolome. In 
this study we aimed to characterize the effects of progesterone on 
the global metabolic profile and explore the differences between 
women with PMDD and controls. 
Methods: Plasma was obtained from 12 women with prospectively 
confirmed PMDD and 25 controls under 2 hormone conditions: 1) 
gonadal suppression induced by leuprolide acetate (3.75mg IM 
monthly) and 2) add-back phase with leuprolide and progesterone 
(200mg twice daily by vaginal suppository). The global metabolic 
profile was obtained using liquid and gas chromatography followed 
by mass spectrometry. Differences between groups and time points 
were tested using repeated measures analysis of variance. The 
false discovery rate was calculated to account for multiple testing.   
Results: Amino acids and their derivatives represented 78% 
(28/36) of the known compounds that were found in significantly 
lower plasma concentrations after progesterone administration than 
during gonadal suppression. The concentration of tyrosine was 
nominally significantly decreased after progesterone add-back in 
controls, but not in cases (p=0.02).  
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Conclusion: Plasma levels of some amino acids are decreased in 
response to progesterone. Albeit preliminary, evidence further 
suggests that progesterone has a different effect on the metabolic 
profiles of women with PMDD compared to controls. Further 
research is needed to replicate our findings in a larger sample and 
to identify the unknown compounds, especially those differentially 
expressed. 
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Introduction 
Premenstrual dysphoric disorder (PMDD) is characterized by 
affective, cognitive, behavioral, and somatic symptoms that are 
limited to the late luteal phase of most menstrual cycles, cause 
significant impairment, and that do not represent an exacerbation 
of a concurrent psychiatric disorder (American Psychiatric 
Association, 2013). Prevalence estimates range between 1 and 6% 
(Gehlert, Song, Chang, & Hartlage, 2009; Wittchen, Becker, Lieb, 
& Krause, 2002) in women of reproductive age. 
Evidence from naturalistic studies and hormone manipulation 
protocols suggests that PMDD is characterized by an abnormal 
response to normal concentrations of progesterone (Dubey et al., 
2017; Parry, Javeed, Laughlin, Hauger, & Clopton, 2000; Roca et 
al., 2003; Schmidt, Nieman, Danaceau, Adams, & Rubinow, 1998; 
M. J. Smith, Adams, Schmidt, Rubinow, & Wassermann, 2002; 
Sundström et al., 1998), rather than abnormal basal hormone levels 
(Rubinow et al., 1988). In the context of ovarian suppression, 
progesterone precipitates affective symptoms in women with 
PMDD, but not in controls without PMDD, suggesting a vulnerability 
to progesterone in PMDD (Schmidt et al., 1998). 
The molecular mechanisms underpinning the progesterone-
triggering mood symptoms in vulnerable women are unknown. The 
inter-individual variability in sensitivity to progesterone can be due 
to a number of differences at the genomic, molecular, cellular, and 
tissue level. Cell metabolism is a potential source of variability. 
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Compared to the study of genes and proteins, that of metabolites 
(i.e. the small molecules that are produced by cell metabolism) has 
several advantages: metabolites are not subject to epigenetic or 
post-translational modifications and present less inter-individual 
variability than the genome (Patti, Yanes, & Siuzdak, 2012).  
Very little is known about the effect of progesterone sensitivity on 
the metabolome. The only study published so far focused on the 
steroid metabolome and did not observe any differences in the 
formation of progesterone derived neurosteroids (Nguyen et al., 
n.d.). It still remains unclear whether progesterone has effects on 
the general metabolome, which includes many neuroregulatory 
small molecules.  
The mechanisms of action of progesterone in vivo are difficult to 
disentangle because high levels of progesterone are always 
concurrent with estrogen elevation  and may vary between subjects. 
Reproductive axis suppression followed by hormone addback is the 
gold standard methodology to isolate the independent effects of 
progesterone and to test causal inference (Stachenfeld & Taylor, 
2014). The suppression-administration protocols consist of two 
phases: 1) a temporary suppression of the menstrual cycle with 
gonadotropin-releasing hormone agonists and 2) the administration 
of estradiol and/or progesterone. 
Consequently, we have performed an opportunistic pharmaco-
metabolomics study, combining  a hormone suppression-
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administration protocol with high-throughput, untargeted 
metabolomics to: 
1. characterize the global metabolic profile of eumenorrheic 
women during gonadal suppression and progesterone 
replacement 
2. explore the differences in the global metabolic profiles 
between cases of PMDD and controls. 
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Material and methods 
Subjects 
The study was performed on 37 women, 12 affected by PMDD and 
25 controls, all eumenorrheic.  
Women with PMDD were recruited via advertisements in the local 
newspapers or through their physicians. The diagnosis of PMDD 
was based on the criteria outlined by the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV)(American 
Psychiatric Association., 2000) and was confirmed prospectively by 
daily self-reports for three months using a three-item 100-mm visual 
analogue scale assessing the timing and severity of mood 
symptoms (Rubinow, Roy-Byrne, Hoban, Gold, & Post, 1984). 
Women completed also the Daily Rating Form, consisting in 4 
questions on distress and functional disability. The Daily Rating 
Form was then combined with a semi-structured interview and a 
self-report questionnaire (both in-house tools) in order to confirm 
that women met the number of symptoms required by the DSM-IV 
criteria. Our definition of PMDD was more stringent than that 
proposed by both DSM-IV and 5, as it included a severity criterion 
for the symptoms disclosed. Our severity criterion required a 30% 
or greater increase in the mean ratings of negative mood symptoms 
in the week before the menses compared with the week after 
menses in at least two of the three menstrual cycles rated.  
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Women who reported similar or higher levels of symptoms and 
impairment in the follicular phase compared to the luteal phase 
were excluded.  
Controls were recruited via advertisement. The lack of 
premenstrual symptoms was ascertained using the same daily 
ratings used for cases for two months.    
Exclusion criteria included the following: psychiatric and medical 
comorbidities, being pregnant and taking medications. Women in 
the PMDD group were included if they had not experienced any 
psychiatric disorders within the previous two years, while none of 
the controls had ever had a psychiatric diagnosis, as assessed by 
the Structured Clinical Interview for the Diagnostic Statistic Manual 
of Mental Disorders (First, Spitzer, Gibbon, & Williams, 2012). All 
women had a normal physical examination, including laboratory 
testing. 
We requested that all women did not take any medications or 
supplements for the duration of the study. 
All participants provided written informed consent and were paid for 
their participation according to the guidelines of the National 
Institutes of Health – Normal Volunteer Office. The protocol was 
approved by the National Institute of Mental Health - Intramural 
Research Review Subpanel and the Food and Drug Administration. 
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Hormone manipulation protocol 
The hormone manipulation protocol consisted of two phases (figure 
1): 
 Gonadal suppression: subjects received monthly injections of 
the gonadotropin-releasing hormone agonist leuprolide acetate 
(3.75 mg i.m.), starting between 2 and 6 days after the onset of 
the menses for at least 8 weeks.  At the end of the gonadal 
suppression phase, a fasting plasma sample was taken (time 
1). 
 Progesterone add-back: the women entered a 4 week add-back 
phase, during which progesterone vaginal suppositories, 200 
mg b.i.d., were administrated together with the monthly injection 
of leuprolide. At the end of the 4 weeks, another fasting plasma 
sample was taken (time 2). 27 (10 cases and 17 controls) of the 
37 women entered the progesterone add-back phase 
immediately following the gonadal suppression phase; for 3 of 
the 27 women, the add-back phase consisted of both 
progesterone and estradiol. The remaining 10 women (2 cases 
and 8 controls) entered the progesterone add-back phase after 
5 weeks of estradiol, 0.1 mg per day, followed by 2-week 
washout. The proximity of estradiol administration to receiving 
progesterone did not affect mood ratings and progesterone 
plasma levels that were similar across groups treated with 
different hormone protocols (Supplemental table 1). 
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Metabolomic analyses 
Metabolomic analyses were performed by Metabolon 
(http://www.metabolon.com). Details on the methodology are 
described elsewhere(Suhre et al., 2011).  
In brief, serum samples (100μL) were extracted and analyzed in a 
platform including two separate ultrahigh-performance liquid 
chromatography/ tandem mass spectrometry injections 
(UHPLC/MS/MS2) and one gas chromatography/mass 
spectrometry (GC/MS) injection.  
Retention time, molecular mass to charge ratio (m/z), preferred 
adducts and in-source fragments were used to identify metabolites 
by comparison to a standard library curated by Metabolon.  
The study data met Metabolon’s quality control standards.  Matrix 
data showed a median Relative Standard Deviation (RSD) of 17% 
for GC/MS and 15% UHPLC/MS. The comparable variation in the 
overall study samples was 45% median RSD (excluding very 
sparsely detected compounds).   
Statistical analyses 
Data were normalized by registering the median values for each 
run-day block.  Comparisons between groups (PMDD cases and 
controls) and time points (gonadal suppression and progesterone 
add-back) were conducted using the repeated measures analysis 
of variance (ANOVA). For ANOVA tests, missing values were 
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imputed with the minimum observed value for the particular 
compound after block-normalization procedure.    
To assess the potential confounding effect of the proximity to 
estradiol administration, we first compared plasma concentrations 
of progesterone and nominally significant metabolites in the three 
groups undergoing different hormone manipulation protocols. Then 
we run sensitivity analyses excluding the three women taking 
progesterone and estradiol at the same time. 
The false discovery rate was calculated to account for multiple 
testing. Q-values are the adjusted p-values obtained using the 
false discovery rate approach. A q-value below 0.1 is an indication 
of high confidence in a hit, while higher q-values indicate 
diminished confidence but do not necessarily rule out the 
significance of a compound.    
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Results 
Sample characteristics are reported in table 1. Cases and controls 
did not statistically differ in age, body mass index, and progesterone 
or estradiol concentrations.  
The proximity of estradiol administration to receiving progesterone 
did not affect mood ratings and progesterone plasma levels that 
were similar across groups treated with different hormone 
protocols. 
While controls did not manifest mood symptoms during the 
manipulation protocol, in women with PMDD we observed few 
affective symptoms during ovarian suppression and the recurrence 
of typical PMDD symptomatology after administration of 
progesterone. Steiner–Carroll scale self- and observer- reported 
symptom scores did not differ between cases and controls during 
leuprolide administration (suppression phase of the hormone 
manipulation protocol - Kruskal-Wallis chi-squared = 9.64, df = 8, p 
= 0.29 and Kruskal-Wallis chi-squared = 8.76, df = 10, p = 0.55 
respectively). Controls remained asymptomatic during hormone 
replacement with progesterone (paired Wilcoxon signed rank test V 
= 89.5, p = 0.10  for self-reported scores, and V = 128, p = 0.67 for 
observer reported scores), while symptoms significantly increased 
in cases during treatment with leuprolide plus progesterone as 
compared with treatment with leuprolide alone (paird Wilcoxon 
signed rank test = V = 3, p = 0.005 for self-reported scores, and  
and V = 0, p = V = 0, p = 0.004 for observer reported scores). 
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Following full data curation, the serum study yielded 407 
compounds.  Approximately one third of these corresponded to 
identifiable chemical entities, and the remaining two thirds 
represented unknown metabolites. More than 41% of the chemicals 
detected were measurable in all the samples, 82% in more than 
two-thirds. Among detectable compounds, there was a 
preponderance of amino acids and their derivatives, which 
represented 44% of the known compounds detected. Other types 
of detected compounds included the following: carbohydrates 
(11%), vitamins and co-factors (8%), compounds involved in energy 
and tricarboxylic acid cycle (6%). Lipids (12%), nucleotides (9%), 
peptides (4%) and xenobiotics (5%).  
Effects of progesterone on the metabolic profile  
Of the 36 known compounds that showed nominally significantly 
(p<0.05) lower plasma levels as a result of progesterone 
administration (table 2), 28 were amino acids or their derivatives. 
Amino acid pathways affected by progesterone involved the 
metabolism of arginine and proline, lysine, threonine, tyrosine, and 
methionine. 
The most dramatic change after administration of progesterone was 
an approximately 28-fold increase in the mean concentration of an 
unknown compound (measured mass: 400.2). There were two 
other unknowns (measured masses: 398.2160 and 384.1636) that 
exhibited a similar response but with not so large an increase. The 
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changes after progesterone administration were significant (p<0.01 
and q<0.1) and similar in controls and PMDD subjects. All these 
compounds had mass values that were consistent with them being 
steroid hormone derivatives.  Mass queries in the Kyoto 
Encyclopedia of Genes and Genomes (Kanehisa & Goto, 2000) 
yielded potential identities. The top two compounds appeared to be 
sulfated versions of immediate progesterone metabolites 
(pregnanediol-sulfate, mass: 400.2278) and (3-OH-5beta-
pregnane-20-one-sulfate, mass: 398.2122).  The third compound’s 
mass was consistent with it being a sulfated version of one of 
several steroid derivatives, all androgens (hydroxyl-DHEA-sulfate 
or 7alpha-hydroxytestosterone-sulfate or 19-hydroxytestosterone 
sulphate, mass: 384.1601).   
 
Differences in metabolic profile between cases with PMDD and 
controls 
Of the 15 compounds that differed between women with PMDD and 
controls in both phases of the hormone manipulation protocol, 7 
were amino acids or their derivatives (table 3). Differences between 
cases of PMDD and controls were more pronounced after 
progesterone add-back than during gonadal suppression (table 3).  
 
Many compounds had a different response to progesterone in 
women with PMDD and in controls (table 4). Although these 
differences were nominally significant (p<0.05), the false discovery 
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rates were above 0.1. The interaction of time by group on ANOVA 
yielded 6 nominally significant hits for amino acids and their 
derivatives: isoleucine (p=0.040), N(‘6)-trimethyl-l-lysine (p=0.047), 
tyrosine (p=0.020 –figure 2), trans-4-hydroxyproline (p=0.045), 
gamma-L-glutamyl-L-tyrosine (p=0.022); and carnitine (p=0.045). 
In each case, the concentrations increased on progesterone in the 
PMDD women and decreased in the controls (4 compounds) or 
decreased to a lesser degree in patients compared with controls (2 
compounds). The concentration of citric acid, involved in the citric 
acid cycle in the mitochondria, was increased after progesterone 
add-back in cases of PMDD, but not in controls.  
The plasma levels of several unknown compounds were also 
altered in response to progesterone in controls or in cases but not 
in both (leading to a nominally significant interaction term). 
Additionally, there were sparse compounds that were exclusively 
expressed in cases or in controls. The concentration of an unknown 
sparse compound (measured mass 346.2) had an increase about 
8 times greater in women with PMDD than in controls following 
progesterone add-back. In controls (but not in cases), the 
concentrations of three unknown sparse compounds were 
increased over 2-fold after the administration of progesterone. 
Salicylate, salicylurate, serotonin, and 4 unknown compounds were 
exclusively found in women with PMDD and increased after the 
administration of progesterone.   
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Discussion 
Effect of progesterone on amino acid metabolism 
Using a hormone manipulation protocol, we found that 
progesterone significantly decreases the concentration of amino 
acids and related compounds in the context of ovarian suppression. 
Our study confirms previous indirect, uncontrolled, observations 
concerning the effect of gonadal steroids on the metabolism of 
amino acids and related compounds (supplemental table 2). In 
contrast to our study, however, previous research has not been able 
to test the causal relationship and examine the effects of 
standardized levels of progesterone, separately from those of other 
hormones. 
The amino acid drop following progesterone add-back could result 
either from faster utilization (e.g., increased protein synthesis 
demands) or from increased catabolism, with evidence pointing to 
both mechanisms (48). (30 (6). 
Our findings represent the first demonstration in humans that 
progesterone administered under controlled conditions alters the 
metabolome. As such, reproductive-steroid induced changes in the 
metabolome, small molecules that are fundamental to cell signaling 
and function, may represent a significant albeit indirect means by 
which steroids regulate processes relevant for brain and behavior. 
Animal and cell culture studies, in fact, suggest both sex differences 
and an effect of reproductive steroids in the metabolism of proteins 
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that affect a broad range of pathological and physiological events 
(Comitato, Saba, Turrini, Arganini, & Virgili, 2015; G. I. Smith et al., 
2014) 
Differential response to progesterone in women with PMDD 
compared to controls 
Our study provides the first evidence of a different metabolic 
response to progesterone in women with PMDD compared to 
controls and requires corroboration or additional work to determine 
false discoveries from truly significant biomarkers. Nonetheless, 
this observation is consistent with other data suggesting an 
abnormal response to progesterone in PMDD, including the 
following (seen in women with PMDD compared with controls): 
precipitation of affective symptoms by progesterone in the context 
of ovarian suppression (Schmidt et al., 1998); absent luteal phase 
increase in the hypothalamic–pituitary–adrenal axis activity (Roca 
et al., 2003) and pregnanolone-stimulated sedation (Sundström et 
al., 1998); lack of cortical inhibition (M. J. Smith et al., 2002) and 
advance in cortisol acrophase(Parry et al., 2000) during the luteal 
phase. 
We found that amino acids involved in the structure and function of 
collagen (trans-4-OH-proline), cell metabolism (carnitine), protein 
(isoleucine and tri-methyl-lysine) and catecholamine synthesis 
(tyrosine) had a different response to progesterone in cases and 
controls.  
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If confirmed in a larger independent sample, our results would 
suggest that the differential sensitivity to progesterone in women 
with PMDD may be reflected in, and potentially mediated by, a 
blunted metabolic response to progesterone, an abnormality 
revealed in the periphery and presumably the central nervous 
system.  
It is not clear how the different sensitivity to progesterone in cases 
of PMDD compared to controls can influence the concentrations of 
some plasma amino acids, but not others. It is possible that women 
with PMDD have an impaired response to the metabolic and 
homeostatic signaling of progesterone. Women with PMDD 
compared to controls may also have increased absorption or 
decreased clearance or dietary consumption of certain amino acids 
in response to progesterone.  
Diet composition also impacts metabolomic profile (Esko et al., 
2017). In this respect, it is interesting that plasma levels of 
exogenous substances as salicylates (found in foods) and caffeine 
were increased after progesterone administration in women with 
PMDD, but not controls. As supplements and drugs were prohibited 
for the duration of the study, this observation suggests that 
differences between cases and controls after progesterone 
administration may be, at least in part, due to changes in quantity 
and quality of ingested foods. The association between PMDD and 
diet, including caffeine consumption (Rossignol & Bonnlander, 
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1990), is, however, controversial, supported by little evidence and 
largely based on retrospective, cross-sectional studies.   
We found that the concentration of tyrosine, a precursor of the 
neurotransmitters dopamine, epinephrine and norepinephrine, was 
decreased after progesterone administration in 80% (N=20) of 
healthy controls, but only in 42% of cases with PMDD (N=5) -figure 
2. Interestingly, we did not find any differences between cases and 
controls in some other obvious candidate neurotransmitter 
precursors, such as tryptophan, while serotonin was detected as a 
sparse compound only in cases. Although the lack of an effect can 
be due to the limited sample size, our results are in agreement with 
previous evidence of a lack of association between tryptophan and 
premenstrual syndrome (Rapkin, Reading, Woo, & Goldman, 
1991). There is a dearth of information on the effect of progesterone 
on the metabolism of catecholamines in humans. Animal brain 
studies have suggested that progesterone affects the activity of 
tyrosine hydroxylase, the enzyme that hydroxylates tyrosine to 3-4-
dihydroxyphenylalanine, but the exact mechanisms are unknown 
and likely to be complex (Tekin, Roskoski, Carkaci-Salli, & Vrana, 
2014). If replicated, our results may suggest that women with 
PMDD have a blunted or absent effect of progesterone on the 
availability of the catecholamine precursor tyrosine. We speculate 
that this leads to a reduced utilization of tyrosine for the synthesis 
of catecholamines during luteal phase in women with PMDD 
compared to controls.  
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 Limitations 
Our results should be interpreted in light of the following limitations: 
 Because of the small size of the sample with PMDD, the 
false-discovery test did not yield significantly low q-values 
in the comparisons between cases and controls. While 
some metabolic changes observed selectively in cases or 
controls may be false discoveries, some were likely 
significant and are consistent with previous, indirect 
evidence of a role of progesterone in metabolism. 
 Although metabolite databases have largely improved in 
the last decade, there are still many poorly characterized 
metabolites with unknown chemical structure and function. 
In particular, we were not able to identify three steroid 
derivatives, whose concentrations were dramatically 
increased after administration of progesterone.  
 Women differed in the proximity of estradiol administration 
to receiving progesterone. However, we did not find any 
differences in mood ratings, progesterone or tyrosine 
plasma levels between groups undergoing different 
hormone protocols. Moreover, we were able to replicate the 
time-by-group interaction for tyrosine in the sub-analyses 
accounting for differences in the proxy and in the sensitivity,  
analyses excluding the three women taking estradiol 
together with progesterone.  
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 We did not collect information on women’s diet and 
therefore cannot exclude that the differences we observed 
between cases and controls are due to different changes in 
the diet in response to progesterone administration. 
Changes in diet in women with PMDD, but not in controls, 
however, are unlikely to be the sole explanation for our 
findings, as we found that changes in amino acid 
concentrations after progesterone were more pronounced 
in controls than cases.  
Conclusion 
In this pharmaco-metabolomics, hypothesis-generating study, we 
report a decrease in plasma levels of amino acids in response to 
progesterone.  
Further research is needed to replicate our findings in a larger 
sample and to identify the unknown compounds affected by 
progesterone, especially those differentially expressed in response 
to progesterone in women with PMDD and controls. 
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Table 1. Demographics and clinical characteristics of women 
with premenstrual dysphoric disorder (PMDD) and control 
women 
 
  
PMDD CONTROLS 
N 
 
12 25 
age (years) mean±standard 
deviation 
38±6.9  34± 8.1  
body mass index (Kg/m2) mean±standard 
deviation 
23.8 ± 4.25 24.3±3.27  
PMDD symptom severity (Steiner–Carroll 
scale: self-report) 
  
Leuprolide median (range) 1.5 (0-5) 2 (0-17) 
Leuprolide+Progesterone* median (range) 11.5 (3-26) 1 (0-9)** 
* Kruskal-Wallis chi-squared = 17.75, df = 1, p < 0.0001 between 
cases and controls  
**Wilcoxon signed rank test with continuity correction= 3, p = 
0.00532 for Leuprolide v Leuprolide+Progesterone  in cases  
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Table 2. Compounds affected by the administration of 
progesterone. Compounds that narrowly missed statistical cutoff 
for significance 0.05<p<0.10 are also displayed. If the ratio of 
means time2/time1 is less than 1, then the compound was found 
in higher concentrations during gonadal suppression than after 
progesterone add-back. Symbols and abbreviations: Time 1: after 
gonadal suppression; time 2: after progesterone add-back; in bold 
p≤0.05 and q<0.1.
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Time ANOVA 
for the whole 
sample  
Ratio of means 
time 2/time 1 
Time ANOVA in 
cases 
Time ANOVA in 
controls 
BIOCHEMICAL PATHWAY P q In cases 
In 
controls 
P Q P Q 
Alanine Alanine and Aspartate 
Metabolism 
0.175 0.537 0.96 0.75 0.908 0.989 0.030 0.153 
Aspartate 0.020 0.187 0.77 0.63 0.230 0.858 0.017 0.126 
Glutamine Glutamate Metabolism 0.014 0.139 0.68 0.78 0.123 0.858 0.029 0.153 
Threonine 
Glycine, Serine and Threonine 
Metabolism <0.001 <0.001 
0.79 0.64 
0.004 0.357 <0.001 <0.001 
Histamine 
Histidine Metabolism 
0.001 0.018 0.79 0.75 0.041 0.742 0.002 0.027 
Histidine 0.343 0.661 1.02 0.88 0.768 0.989 0.041 0.173 
Isobar 6 Valine, Betaine 
Leucine, Isoleucine and Valine 
Metabolism 0.397 0.661 
1.07 0.85 
0.567 0.979 0.025 0.142 
Alpha-Aminoadipic Acid 
Lysine Metabolism 
0.107 0.422 0.84 0.84 0.455 0.944 0.078 0.255 
Glutarate <0.001 0.007 0.62 0.58 0.023 0.742 <0.001 0.010 
Lysine <0.001 0.007 0.89 0.84 0.036 0.742 <0.001 0.004 
N('6)-Trimethyl-L-Lysine <0.001 0.008 0.90 0.71 0.240 0.858 <0.001 0.000 
Methionine 
Methionine, Cysteine, SAM and 
Taurine Metabolism 0.024 0.208 
1.02 0.78 
0.687 0.989 0.001 0.020 
Alpha-4-Dihydroxybenzenepropanoic 
Acid 
Phenylalanine and Tyrosine 
Metabolism 
0.003 0.055 
0.92 0.88 
0.110 0.858 0.003 0.035 
Thyroxine 0.206 0.576 0.81 1.47 0.834 0.989 0.015 0.113 
Tyramine 0.069 0.354 0.72 0.73 0.315 0.877 0.078 0.255 
Tyrosine 0.093 0.401 1.05 0.82 0.671 0.989 0.001 0.017 
5-Hydroxyindoleacetate 
Tryptophan Metabolism 
0.018 0.169 0.79 0.88 0.069 0.749 0.104 0.281 
3-Indoxyl Sulfate 0.038 0.284 0.87 0.84 0.224 0.857 0.054 0.212 
Serotonin 0.172 0.537 0.94 0.89 0.644 0.989 0.084 0.259 
Arginine 
Urea cycle; Arginine and Proline 
Metabolism 
<0.001 0.003 0.85 0.73 0.036 0.742 <0.001 <0.001 
N(5)-(Aminocarbonyl)-L-Ornithine 0.004 0.062 0.63 0.81 0.008 0.447 0.186 0.369 
Proline 0.009 0.102 0.85 0.83 0.096 0.841 0.024 0.142 
Urea Adduct Of Isobar 6 0.002 0.048 0.99 0.76 0.051 0.749 0.008 0.084 
Cl Adduct Of Uric Acid 0.003 0.055 0.68 0.73 0.063 0.749 0.009 0.089 
Hydroxyproline Form Of Bradykinin 0.014 0.139 0.78 0.71 0.382 0.925 0.002 0.032 
Trans-4-Hydroxyproline <0.001 0.008 0.88 0.60 0.228 0.858 <0.001 <0.001 
Citric Acid TCA Cycle  0.095 0.403 0.83 0.81 0.396 0.926 0.085 0.259 
2-Deoxy-D-Ribose 
Pentose Metabolism  
0.056 0.334 1.32 1.02 0.052 0.749 0.567 0.530 
Xylitol 0.049 0.320 0.79 0.77 0.335 0.881 0.037 0.162 
Alpha-D-Ribose 5-Phosphate Pentose Phosphate Pathway 0.431 0.683 1.03 0.83 0.834 0.989 0.097 0.280 
Pyridoxamine Vitamin B6 Metabolism <0.001 0.011 0.82 0.93 0.001 0.192 0.075 0.255 
Isobar 2  Amino-Butyrates 
Pyrimidine Metabolism, Thymine 
containing 0.002 0.032 
0.84 0.79 
0.068 0.749 0.002 0.031 
L-Carnosine Dipeptide Derivative 0.173 0.537 1.02 0.88 0.972 0.996 0.022 0.142 
Gamma-L-Glutamyl-L-Glutamine 
Gamma-glutamyl amino acid 
0.025 0.215 0.91 0.73 0.332 0.881 0.011 0.096 
Gamma-L-Glutamyl-L-Tyrosine 0.246 0.616 1.14 0.83 0.465 0.944 0.004 0.037 
Tartarate Food Component/Plant 0.008 0.096 0.74 0.77 0.117 0.858 0.014 0.113 
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Table 3. Compounds found in different concentrations in cases of PMDD and controls. 
Compounds that narrowly missed statistical cutoff for significance 0.05<p<0.10, are also 
displayed. Symbols and abbreviations: Time 1: after gonadal suppression; time 2: after 
progesterone add-back. In bold p≤0.05.   
  
Group ANOVA Ratio of 
means 
cases/control 
 Group ANOVA 
at time 1 
Group ANOVA 
at time 2 
BIOCHEMICAL PATHWAY P q At 
time 
1 
At 
time 
2 
P Q P Q 
Alanine Alanine and Aspartate Metabolism 0.134 0.775 0.76 0.97 0.059 0.732 0.865 0.681 
N-Acetyl-L-Aspartic Acid 0.004 0.542 1.62 1.89 0.033 0.732 0.007 0.465 
Isobar 6 Valine, Betaine Leucine, Isoleucine and Valine 
Metabolism 
0.364 0.838 0.86 1.10 0.065 0.732 0.632 0.672 
Tyrosine Phenylalanine and Tyrosine 
Metabolism 
0.566 0.877 0.95 1.23 0.492 0.997 0.095 0.596 
N(5)-(Aminocarbonyl)-L-Ornithine Urea cycle; Arginine and Proline 
Metabolism 
0.102 0.775 0.94 0.72 0.633 0.997 0.028 0.596 
Trans-4-Hydroxyproline 0.254 0.807 1.07 1.57 0.906 0.997 0.056 0.596 
Glycerol-2-Phosphatase Glycolysis, Gluconeogenesis, and 
Pyruvate Metabolism 
0.012 0.542 0.85 0.96 0.067 0.732 0.227 0.596 
Glycerate 0.125 0.775 0.83 0.96 0.065 0.732 0.290 0.611 
Alpha-D-Ribose 5-Phosphate Pentose Phosphate Pathway 0.024 0.542 0.78 0.97 0.022 0.732 0.601 0.672 
Biliverdin Hemoglobin and Porphyrin 
Metabolism 
0.325 0.807 1.35 0.96 0.996 0.997 0.084 0.596 
Pyridoxamine Vitamin B6 Metabolism 0.015 0.542 0.91 0.81 0.219 0.930 0.003 0.307 
Isobar 2  Amino-Butyrates Pyrimidine Metabolism, Thymine 
containing 
0.035 0.615 1.11 1.18 0.167 0.930 0.069 0.596 
Uridine Pyrimidine Metabolism, Uracil 
containing 
0.051 0.723 0.74 0.79 0.054 0.732 0.189 0.596 
Gamma-L-Glutamyl-L-Tyrosine Gamma-glutamyl Amino Acid 0.038 0.615 1.07 1.46 0.537 0.997 0.003 0.307 
Caffeine Xanthine Metabolism 0.044 0.674 1.59 1.97 0.111 0.831 0.043 0.596 
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Table 4. Compounds with different changes in concentration at time 1 and time 2 
between cases of PMDD and controls (i.e. time by group interaction). If T2/T1 ratio is 
greater than 1, the compound was found in higher concentrations after progesterone 
administration than during gonadal suppression. If PMDD/CONTR ratio is greater than 1, the 
compound was found in higher concentrations in cases than in controls. Symbols and 
abbreviations: T1: after gonadal suppression; T2: after progesterone add-back. In bold p≤0.05.   
  
 
Group by time interaction ANOVA 
Fold-Change (Ratios of Means from Scaled Imputed Data) 
 T2/T1 PMDD/CONTR 
BIOCHEMICAL PATHWAY p Q PMDD CONTROL T1 T2 
Unknown Compound N/A 0.012 0.850 1.28 0.89 0.78 1.12 
Tyrosine Phenylalanine and Tyrosine Metabolism 0.020 0.850 1.05 0.82 0.95 1.23 
Gamma-L-Glutamyl-L-Tyrosine Gamma-glutamyl Amino Acid 0.022 0.850 1.14 0.83 1.07 1.46 
Unknown Compound N/A 0.030 0.850 0.70 1.63 1.90 0.81 
Citric Acid N/A 0.033 0.850 1.21 0.87 0.73 1.01 
Unknown Compound N/A 0.036 0.850 1.25 0.80 0.60 0.93 
Isoleucine Leucine, Isoleucine and Valine Metabolism 0.040 0.850 1.44 0.85 0.87 1.49 
Unknown Compound N/A 0.044 0.850 0.80 1.51 1.70 0.89 
Carnitine-1 N/A 0.045 0.850 1.23 0.78 0.81 1.28 
Trans-4-Hydroxyproline Urea cycle; Arginine and Proline Metabolism 0.045 0.850 0.88 0.60 1.07 1.57 
N('6)-Trimethyl-L-Lysine Lysine Metabolism 0.047 0.850 0.90 0.71 0.97 1.24 
Unknown Compound N/A 0.049 0.850 0.82 1.00 1.21 0.99 
 
